Malattia di Charcot-Marie-Tooth

La malattia di Charcot-Marie-Tooth o CMT o Hereditary Motor and Sensory Neuropathy (HMSN), nota anche come Neuropatia motorio-sensitiva ereditaria, è una sindrome neurologica ereditaria a carico del sistema nervoso periferico. Deve il suo nome ai tre medici che per primi la descrissero: Jean-Martin Charcot, Pierre Marie, e Howard Henry Tooth. Con il nome CMT sono indicate molte malattie, con sintomi anche estremamente diversi, la forma di gran lunga più diffusa è la 1A, che si caratterizza per perdita di tono muscolare e della sensibilità al tatto, in particolare agli arti inferiori al di sotto del ginocchio; meno frequentemente, e in genere negli stadi più avanzati della malattia, gli effetti si notano anche negli arti superiori al di sotto del gomito. Allo stato attuale non esistono cure, sebbene la CMT sia la malattia più diffusa tra le sindromi neurologiche ereditarie, con 36 casi di insorgenza ogni 100.000 nascite. In Italia è classificata dal Ministero della Sanità come malattia rara. Può essere associata al diabete mellito. (fonte: Wikipedia)
Comunicati Stampa

Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update

Addex Therapeutics / Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 9 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today: Financial Update Addex completed 2014 with cash and cash... (Thomson Reuters - 09/01/2015) Leggi

Pharnext's Pleotherapy Shows Synergistic Effects with PXT-864 in Alzheimer's Disease through Preclinical Data Published in Nature's Scientific Reports

PARIS, Jan. 8, 2015 /PRNewswire/ -- Pharnext SAS today announced the publication of preclinical results in Nature's Scientific Reports for its lead pleodrug, PXT-864, in Alzheimer's disease. These data further validate its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. (PR Newswire - 08/01/2015) Leggi

La pleoterapia de Pharnext muestra efectos sinérgicos con PXT-864 en la enfermedad de Alzheimer

- Los datos preclínicos ofrecen más validación del enfoque de pleoterapia de Pharnext (PR Newswire - 08/01/2015) Leggi

Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder

Addex Therapeutics / Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 7 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the National Institute on... (Thomson Reuters - 07/01/2015) Leggi

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications

- First Paper Shows Consistent and Synergic Preclinical Data for PXT-3003 in Two Different CMT 1A Rodent Models - (PR Newswire - 18/12/2014) Leggi
1 2 3 4 5 6
Altri nomi: CMT, Morbus Charcot-Marie-Tooth, Hereditary motor and sensory neuropathy, Charcot-Marie-Tooth neuropathy, Hereditary sensory motor neuropathy, Peroneal muscular atrophy, Hereditary sensorimotor neuropathy, HSMN, Charcot-Marie-Tooth disorder